Islamabad's SIFC-backed national initiative, unveiled at the Pakistan Association of Plastic Surgeons conference, positions the country as an emerging low-cost, high-quality alternative — just as China's own nine-ministry medical visa policy seeks to attract more international patients.
Pakistan formally launched its Pakistan National Medical Tourism Initiative on April 14, 2026, under the oversight of the Special Investment Facilitation Council (SIFC) — a body designed to fast-track strategic investment into the country. The announcement, reported by ProPakistani, marks a rare formalised government push to position Pakistan as a regional destination for affordable, quality medical care.
The initiative was unveiled during the 30th annual conference of the Pakistan Association of Plastic Surgeons, held at the Pakistan Institute of Medical Sciences in Islamabad. The conference drew more than 400 delegates and a slate of international experts, including specialists Eva Maria and Nick Wilson John, representing the kind of global collaboration Islamabad hopes will lend credibility to its medical tourism ambitions.
Health Secretary Aslam Ghauri and SIFC Director General Asadur Rehman Cheema framed the initiative as a direct response to growing demand from international patients seeking cost-effective treatment in the region. The emphasis was squarely on affordability and quality — a formula already well-established in competing markets like India, Thailand, and Malaysia.
At the core of Pakistan's pitch is cost competitiveness. The SIFC-led initiative aims to offer international patients treatments at a fraction of what they would pay in Western countries, without sacrificing clinical quality. The plastic surgery conference itself — focused on Botox, fillers, reconstructive surgeries, and other modern aesthetic procedures — signals the country's intent to compete not just on pricing but on the range of specialties it can offer.
The telemedicine dimension adds another layer. Pakistan's Sehat Kahani platform, which provides teleconsultation services, has expanded to eight facilities in Islamabad and Karachi, serving thousands of patients. Officials say the telemedicine programme has saved approximately Rs8 million by reducing travel costs — with women comprising 65% of beneficiaries. While telemedicine itself is not a medical tourism draw in the traditional sense, it represents an infrastructure foundation that could support pre- and post-operative remote care for international patients.
There are obvious headwinds. Pakistan faces image challenges as a medical tourism destination — not least of which are regional security perceptions and the absence of a mature international patient brand comparable to Malaysia or Thailand. The country will need to build accredited hospital infrastructure, English-language service capacity, and a marketing apparatus comparable to its rivals.
China is not standing still. The nine-ministry policy framework released in 2026 established a coordinated mechanism for attracting foreign patients through faster medical visas, streamlined hospital admission processes, and expanded English-language capacity at designated international hospitals. The focus areas — proton therapy for cancer, robotic surgery, IVF and fertility treatment, and traditional Chinese medicine — represent clinical capabilities that most regional competitors cannot match.
Where China competes less effectively is on price transparency and ease of access. Visa requirements, language barriers at the hospital level, and a less developed international patient brand have historically kept China from capturing a larger share of the medical tourism market relative to Thailand or Malaysia. The nine-ministry policy is designed to address exactly these gaps.
Sehat Kahani's telemedicine model in Pakistan also has a parallel in China's own digital health infrastructure — major Chinese hospitals have invested heavily in remote consultation platforms for international patients, though the scale and accessibility of Pakistan's government-coordinated programme is notable as a potential model.
| Factor | Pakistan (New Initiative) | Malaysia (MYMT 2026) | China (2026 Policy) |
|---|---|---|---|
| Government Support | SIFC-backed national initiative, formally launched April 2026 | Malaysia Year of Medical Tourism (MYMT) 2026, full government campaign | Nine-ministry coordinated policy, medical visa framework |
| Market Stage | Emerging / Early stage | Established, top 10 globally (Nomad Capitalist ranking) | Developing, strong in specific specialties |
| 2024 Revenue / Volume | Not yet formally tracked | 1.6M healthcare travellers, RM2.72B revenue (2024) | Growing, precise figures not publicly comparable |
| Revenue Target | TBD — initiative newly launched | RM12–15B spillover by 2030 | Expanding international patient volume target |
| Key Specialties | Plastic surgery, reconstructive, telemedicine-supported care | Multi-specialty, IVF, cardiology, oncology | Proton therapy, robotic surgery, TCM, IVF, orthopaedics |
| Cost Advantage | High — positioned as low-cost regional option | Moderate — competitive within ASEAN | Moderate to high for advanced procedures |
| Brand / International Recognition | Low — building from base | High — "Healing Meets Hospitality" brand, Siti Nurhaliza ambassador | Moderate — improving via JCI accreditation |
| Entry Requirements | Standard visa; initiative may simplify process | Standard tourist/reasonal entry; no mandatory insurance | Medical visa with sponsor hospital documentation |
| Telemedicine Infrastructure | Sehat Kahani — 8 facilities, 65% women beneficiaries | Developing across private hospital networks | Advanced at top-tier international hospitals |
| Major Risk Factor | Regional perception, infrastructure gaps | Competition from lower-cost neighbours | Language barriers, visa complexity |
Pakistan's push adds competitive pressure, but it also underscores a broader trend: the Asia medical tourism market is growing and fragmenting into specialised niches. Malaysia is the established brand. Thailand focuses on wellness and aesthetics. India draws on cost and volume. And now Pakistan is entering as an ultra-low-cost option with growing surgical expertise.
China's best defence is not to compete on price against Pakistan or India, but to double down on the clinical areas where it has structural advantages — particularly proton therapy, complex oncology, robotic surgery, and integrative traditional Chinese medicine. The nine-ministry medical visa policy is a good start, but converting policy into a recognisable international patient brand will require sustained investment in English-language hospital services, price transparency, and international accreditation.
The opportunity is real: the global medical tourism market's 12.3% annual growth means the pie is expanding for everyone. Whether China captures a larger slice depends on how effectively it can translate its clinical strengths into a patient experience that international travellers actually want.
Whether you're considering proton therapy, robotic surgery, or integrated traditional Chinese medicine, China Hospitals Guide connects you with internationally accredited hospitals offering consultations, cost estimates, and care coordination for international patients.
Browse Partner Hospitals